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Stephen J Freedland4,5,6,7, Cathrine Hoyo1 and Delores J Grant2*Abstract
Background: We have previously shown that a functional polymorphism of the UGT2B15 gene (rs1902023) was
associated with increased risk of prostate cancer (PC). Novel functional polymorphisms of the UGT2B17 and
UGT2B15 genes have been recently characterized by in vitro assays but have not been evaluated in
epidemiologic studies.
Methods: Fifteen functional SNPs of the UGT2B17 and UGT2B15 genes, including cis-acting UGT2B gene SNPs, were
genotyped in African American and Caucasian men (233 PC cases and 342 controls). Regression models were used
to analyze the association between SNPs and PC risk.
Results: After adjusting for race, age and BMI, we found that six UGT2B15 SNPs (rs4148269, rs3100, rs9994887,
rs13112099, rs7686914 and rs7696472) were associated with an increased risk of PC in log-additive models
(p < 0.05). A SNP cis-acting on UGT2B17 and UGT2B15 expression (rs17147338) was also associated with increased
risk of prostate cancer (OR = 1.65, 95% CI = 1.00-2.70); while a stronger association among men with high Gleason
sum was observed for SNPs rs4148269 and rs3100.
Conclusions: Although small sample size limits inference, we report novel associations between UGT2B15 and
UGT2B17 variants and PC risk. These associations with PC risk in men with high Gleason sum, more frequently found
in African American men, support the relevance of genetic differences in the androgen metabolism pathway, which
could explain, in part, the high incidence of PC among African American men. Larger studies are required.Background
Prostate cancer is the second leading cause of cancer-
related deaths in men, after lung cancer [1]. The incidence
of prostate cancer has increased over the past twenty years
and African American men have been disproportionally
affected compared to other racial/ethnic groups [2-7]. In
the U.S., the incidence of prostate cancer among African
Americans is more than 60% higher than in Caucasians,
and the mortality rate in African Americans is twice that
of Caucasian men [8,9]. Although differences in incidence
and mortality rates may be due, in part, to race/ethnicity,
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reproduction in any medium, provided the or[10], familial aggregation studies suggest that genetic
factors may also be contributing to prostate cancer
demographic disparity. Candidate gene approaches in-
volving hormone metabolic pathways have been exam-
ined in prostate cancer association studies, however
results from these studies have not been replicated
[11,12]. Nonetheless, current therapies are primarily
targeted at specific androgen biosynthetic pathways
[13], thus, improved knowledge on genetic variants as-
sociated with both androgen metabolism and prostate
cancer risk is important.
The UDP-glucuronosyltransferase (UGT) genes code
for enzymes that convert a diverse group of xenobiotic
and endobiotic substances into lipophilic compounds,
facilitating clearance from the body as part of the phased. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subdivided into families according to similarities in
amino acid sequence and target substrates dictated by
the specificity of their amino-terminal ends [15]. A specific
subfamily, UGT2B, includes two enzymes, UGT2B17 and
UGT2B15, which are also expressed extrahepatically in
the basal and luminal epithelium of the prostate, respect-
ively. These enzymes exhibit specificity for androgen me-
tabolites such as testosterone, dihydrotestosterone (DHT),
androsterone (ADT), and androstane-3α,17β-diol (3β-diol)
in prostate tissue and cell lines [16,17].
Functional polymorphisms of the UGT2B gene family
such as the copy number variant (CNV) of UGT2B17,
and the aspartic acid (D or nucleotide G) to tyrosine
substitution (Y or nucleotide T) found in codon 85 of
the UGT2B15 gene (UGT2B15D85Y, rs1902023) have been
identified [18,19]. Studies suggest that men with 0 copies
of the UGT2B17 gene are unable to break down testoster-
one through the UGT2B pathway and subsequently se-
crete negligible amounts of urinary testosterone compared
to men with at least one copy of UGT2B17 [18,20]. Ex-
perimental evidence showed that the minor allele (T) of
the UGT2B15 variant, UGT2B15D85Y, causes the enzyme
to have an increased Vmax activity when compared to the
presence of the major allele (G) [19]. Subsequently, the
resulting phenotype of this UGT2B15 polymorphism is a
quicker androgen metabolite clearance which may raise
the “effective” amount of steroids within the prostate and
decrease risk for prostate cancer [21]. These two major
UGT2B variants (the CNV in UGT2B17 and the poly-
morphism in UGT2B15) have been evaluated in relation
to prostate cancer risk, with inconsistent findings [22-32].
Discrepancies could have been due to the genetic het-
erogeneity of the populations studied, as well as variable
sample sizes of these populations. We have recently
shown that individuals with a major allele (G) of the
UGT2B15D85Y polymorphism (rs1902023) have higher
risk of prostate cancer when compared to individuals
homozygous for the “rapid clearance” minor allele (Y)
[33]. In the same study, the UGT2B17 CNV showed no
association with prostate cancer risk [33]. Recently, an
additional 7 novel UGT2B15 SNPs that are in strong
linkage disequilibrium (LD) with the UGT2B15D85Ygene
variant, have been identified by re-sequencing the pro-
moter and exon one regions of the UGT2B15 gene,
using DNA samples from Yoruba (YRI), CEPH/European
(CEU), and Japanese/Chinese (ASN) populations [34].
Most of these UGT2B variants have not been evaluated in
relation to prostate cancer risk in population-based studies
or in studies that included African American men. In
this present work, we examined associations between
functional SNPs of UGT2B17, UGT2B15 and three
other related UGT2B SNPs, and prostate cancer risk
among African American and Caucasian men.Methods
Study population
The details of participant accrual for this case control
study have been previously reported [35]. In brief, male
subjects from the Durham Veterans Affairs Medical
Center (DVAMC) in Durham, North Carolina, who were
undergoing a prostate needle biopsy between January
2007 and October 2011, were consecutively contacted in
a hospital-based, case control study. Eligibility criteria
for cases included age >18 years, undergoing a prostate
biopsy for concerns of potential prostate cancer after
presentation with elevated PSA and/or abnormal digital
rectal examination, and prostate cancer positive classifi-
cation by pathological review of biopsy tissue. Of the
759 men with a biopsy indication who were screened for
eligibility, 539 (759/539 = 71% participation rate) pro-
vided written consent to participate. Twenty two men
elected not to follow through and of the 517 men that
underwent a biopsy, 233 had a biopsy with histological
evidence of prostate cancer. Controls were recruited
from the DVAMC Internal Medicine Clinic; eligibility
criteria were age >18 and having a PSA test conducted
at the DVAMC within the same time frame, but not rec-
ommended to undergo biopsy. Of the 768 men who met
eligibility criteria for controls, 377 provided written con-
sent (768/377 = 49% participation rate). Questionnaires
were administered to prostate cancer cases prior to biopsy
and to controls to assess risk factors including race and
age. Institutional Review Board approval was obtained at
North Carolina Central University, Duke University, and
the DVAMC and all patients signed an informed consent
prior to enrollment.
Genotyping
UGT2B variants were selected for genotyping from previ-
ous published reports as well as dbSNP and SNP Tags
from the Genome Variation Server (GVS) (Table 1). Eight
were from the UGT2B15 gene, 4 were from the UGT2B17
gene and 3 were cis-acting on the UGT2B15 and/or
UGT2B17 gene expression. UGT2B15 SNPs that were ge-
notyped for this study include rs1580083, rs1960733
(formerly rs34050522), rs9994887 (formerly rs35513228),
rs13112099, rs7866914 (formerly rs34027331), rs7696472,
rs4148296, rs3100 and rs17221777. UGT2B15 SNPs
rs1580083, rs1960733 (formerly rs34050522), rs9994887
(formerly rs35513228), rs13112099, rs7686914 (formerly
rs34027331) and rs7696472 were identified from the re-
sequencing of the UGT2B15 promoter and exon 1 in 56
HapMap samples from YRI, CEU, and East Asian (ASN)
populations [34]. Other UGT2B15 SNPs genotyped,
rs4148296 (T523K) and rs3100 (3′UTR) were charac-
terized by differential allelic expression assays and re-
sequencing, respectively [36]. The final UGT2B15 SNP,
rs17221777, was identified in a previous study [18].
Table 1 UGT2B15 and UGT2B17 genotyped SNPs and Minor alleles
SNP Function class Minor allele/MAF Reference
All Afr. American Caucasian
UGT2B15 SNPs
rs1580083 Promoter T/0.74 0.70 0.80 34
rs1960773 Promoter (Nrf2) T/0.73 0.70 0.76 34
rs9994887 Promoter A/0.73 0.67 0.78 34
rs13112099 Promoter T/0.74 0.70 0.78 34
rs7686914 Promoter T/0.73 0.68 0.78 34
rs7696472 Promoter G/0.73 0.68 0.76 34
rs4148269 Nonsyn (T523K) C/0.70 0.70 0.85 36
rs3100 3′UTR T/0.72 0.53 0.85 36
UGT2B17 SNPs
rs59678213 Promoter (FoxA1) C/0.32 0.24 0.67 37
rs7435827 Intron G/0.60 0.30 0.76 GVS
rs7686008 Intron T/0.18 0.34 0.06 GVS
rs7671342 Intron G/0.41 0.41 0.41 GVS
Cis acting on UGT2B expression
rs6822259^ Intergenic C/0.32 0.30 0.30 38
rs17147338^^ Intergenic T/0.16 0.30 0.079 38
rs2168047^^ Distal promoter A/0.67 0.73 0.63 38
^cis-acting on UGT2B17 expression (36).
^^cis-acting on UGT2B17 and UGT2B15 expression (36).
GVS – genome variation server.
Table 2 Risk factor characteristics for prostate
cancer participants
Risk factors Cases n = 233
n (%)
Controls n = 342
n (%)
p-value
Age - mean (SD) 63.34 (6.37) 61.32 (7.49) p = 0.005
Height (in.) 69.65 (2.92) 69.91 (3.03) p = 0.31
Obesity (BMI) 29.25 (5.60) 30.77 (6.05) p = 0.002
Race p = <.0001
African American 146 (62.66) 140 (40.93)
Caucasian 87 (37.34) 202 (59.06)
Family history PC p = 0.16
Yes 32 (13.73) 34 (9.94)
No 201 (86.26) 308 (90.05)
Tobacco use p = 0.43
Yes 225 (96.56) 334 (97.66)
No 8 (3.43) 8 (2.33)
Gleason sum <8 (134 211 (91.34)
Black/77 White) NA
≥8 (10 Black/10 White) 20 (8.66)
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include rs72551386, rs59678213, rs7435827, rs7686008,
rs7671342, rs35994121, and rs35140421. UGT2B17 SNPs
rs7435827, rs7686008, rs7671342, rs35994121, and rs35140421
were identified as UGT2B17 Tag SNPs in the GVS and
dbSNP databases. UGT2B17 SNP rs59678213 was identi-
fied as a novel polymorphism in a transcriptional binding
site in the promoter region of UGT2B17 [37]. Four SNPs
were genotyped in this study, rs6822259, rs17147338,
rs2168047 and rs4557343, that were identified in a
SNP discovery study and characterized as cis-acting on
UGT2B17 (rs6822259), UGT2B15 (rs4557343), and
UGT2B17 and UGT2B15 (rs17147338, rs2168047) gene
expression [38]. Of the twenty SNPs, five were excluded
from analysis because they were either monoallelic
(rs72551386, rs17221777, rs3599412, and rs3514942) in
the study population or the genotyping assay failed
(rs455734).
DNA was isolated from peripheral blood by standard
DNA isolation (Qiagen Inc., Valencia, CA, U.S.A.) and
quantified by ultraviolet spectrophotometry. Prior to
genotyping, DNA concentration was determined using
PicoGreen assay (Life Technologies, Gaithersburg, MD)
and measured using the fluorescence intensity measure-
ments plotted against a standard curve that was generated
from the average fluorescence intensity of standards run
Table 3 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC
SNP # Allele Cases
n (%)
Controls
n (%)
OR (95% CI)*
UGT2B15
rs1580083
TT 2 (0.86) 5 (1.47) Reference
TA 150 (64.38) 249 (73.45) 2.32 (0.23-23.81)
AA 81 (34.76) 85 (25.07) 3.24 (0.31-33.93)
AA/TA 231 (99.14) 334 (98.52) 2.54 (0.25-26.00)
Log additive 1.43 (0.91-2.26)
rs1960773
TT 1 (0.43) 5 (1.47) Reference
GT 144 (62.61) 244 (71.98) –
GG 85 (36.96) 90 (26.55) –
TT/GT 229 (99.56) 334 (98.52) –
Log additive –
rs9994887
AA 38 (16.31) 91 (26.84) Reference
AG 108 (46.35) 158 (46.61) 1.94 (1.06-3.53)
GG 87 (37.34) 90 (26.55) 2.38 (1.24-4.55)
GG/AG 195 (83.69) 248 (73.15) 2.10 (1.18-3.71)
Log additive 1.49 (1.09-2.04)
rs13112099
TT 38 (16.31) 91 (26.61) Reference
GT 110 (47.21) 163 (47.66) 1.93 (1.06-3.52)
GG 85 (36.48) 88 (25.73) 2.35 (1.22-4.51)
GG/GT 195 (83.69) 251 (73.39) 2.07 (1.12-3.67)
Log additive 1.48 (1.08-2.03)
rs7686914
TT 38 (16.45) 91 (26.84) Reference
CT 109 (47.19) 160 (47.20) 1.94 (1.06-3.55)
CC 84 (36.36) 88 (25.96) 2.34 (1.22-4.50)
CC/CT 193 (83.55) 248 (73.81) 2.10 (1.17-3.70)
Log additive 1.48 (1.08-2.03)
rs7696472
GG 38 (16.31) 92 (26.97) Reference
AG 110 (47.21) 157 (46.04) 2.00 (1.10-3.63)
AA 85 (36.48) 90 (26.39) 2.30 (1.20-4.40)
AA/AG 195 (83.69) 249 (73.02) 2.10 (1.18-3.72)
Log additive 1.49 (1.06-2.00)
rs4148269
CC 43 (18.45) 79 (23.23) Reference
CA 72 (30.90) 160 (47.05) 0.81 (0.45-1.46)
AA 115 (49.35) 101 (29.70) 1.98 (1.02-3.85)
AA/CA 190 (81.54) 261 (76.76) 1.10 (0.63-1.90)
Log additive 1.45 (1.03-2.03)
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Table 3 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC (Continued)
rs3100
TT 54 (23.78) 106 (31.08) Reference
TC 68 (29.95) 140 (41.05) 1.04 (0.60-1.81)
CC 105 (46.25) 95 (27.85) 2.18 (1.19-3.99)
CC/TC 173 (76.21) 235 (68.91) 1.41 (0.86-2.31)
Log additive 1.46 (1.08-1.98)
Cis acting on UGT2B expression
rs2168047
AA 53 (22.84) 59 (17.45) Reference
GA 112 (48.27) 169 (50.00) 0.86 (0.48-1.53)
GG 67 (28.87) 110 (32.54) 1.00 (0.52-1.88)
GG/GA 179 (77.15) 279 (82.54) 0.90 (0.52-1.57)
Log additive 1.01 (0.74-1.38)
rs6822259
CC 3 (1.29) 12 (3.52) Reference
CT 58 (25.00) 97 (28.44) 1.48 (0.36-6.02)
TT 171 (73.70) 232 (68.03) 1.34 (0.34-5.31)
TT/CT 229 (98.70) 329 (96.48) 1.39 (0.35-5.43)
Log additive 1.02 (0.68-1.53)
rs17147338
CC 168 (72.1) 285 (83.58) Reference
CT 55 (23.61) 51 (14.96) 1.68 (0.96-2.97)
TT 10 (4.29) 5 (1.47) 2.41 (0.42-13.94)
TT/CT 65 (27.9) 56 (16.42) 1.73 (1.00-3.00)
Log additive 1.65 (1.00-2.70)
UGT2B17
rs7435827
GG 53 (24.20) 106 (32.61) Reference
GA 43 (19.63) 78 (24.00) 0.67 (0.35-1.30)
AA 123 (56.16) 141 (43.38) 0.90 (0.49-1.66)
AA/GA 166 (75.79) 219 (67.38) 0.80 (0.46-1.38)
Log additive 0.97 (0.71-1.36)
rs7686008
AA 168 (71.79) 281 (82.4) Reference
AT 34 (14.53) 32 (9.38) 1.40 (0.69-2.79)
TT 32 (13.68) 28 (8.21) 1.40 (0.66-2.96)
TT/AT 66 (28.21) 60 (17.6) 1.39 (0.79-2.44)
Log additive 1.21 (0.85-1.73)
rs7671342
GG 37 (15.94) 56 (16.37) Reference
GA 46 (19.83) 85 (24.85) 0.86 (0.43-1.73)
AA 149 (64.22) 201 (58.77) 1.32 (0.73-2.40)
AA/GA 195 (84.05) 286 (83.62) 1.17 (0.65-2.08)
Log additive 1.21 (0.91-1.61)
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Table 3 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC (Continued)
rs59678213
CC 42 (19.44) 81 (25.63) Reference
TC 46 (21.29) 74 (23.42) 0.84 (0.43-1.63)
TT 128 (59.26) 161 (50.94) 0.85 (0.45-1.59)
TT/TC 174 (80.55) 235 (74.37) 0.84 (0.47-1.50)
Log additive 0.92 (0.68-1.26)
*Adjusted for age, race and BMI.
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of genomic DNA from each sample was used in the iPlex
assay for Sequenom-iPlex Genotyping (Sequenom Inc.,
San Diego, CA). The Sequenom Mass Array (Sequenom
Inc., San Diego, CA) was used and the assays for all SNPs
were designed by Sequenom online assay tools (Assay
Designer 4.0) at the David H. Murdock Research Insti-
tute (DHMRI) Genomics Laboratory (Kannapolis, NC).
The data were analyzed by Sequenom-Typer 4.0. The
Sequenom-iPlex genotyping and analysis was validated
with CEPH gDNA controls when performing the iPlex
assay and scanning on the MALDI-TOF Mass Spec-
trometer. At the time of this analysis, 585 samples were
submitted and successfully produced good spectra for
genotyping at a failure rate of <2.2% for the majority of
SNPs. The Post-QC (Call Rate) of SNPs rs59678213 and
rs7435827 was 92.7% and 94.7%, respectively. The assays
included DHMRI control DNA (CEPH) on each plate in
duplicate that were checked for concordance for each
SNP. Sample duplicates were individually inspected for
genotype consistency. Genotypes from duplicate samples
were 100% concordant.
Statistical analysis
We examined whether genetic variants of UGT2B17 and
UGT2B15 genes were associated with prostate cancer
risk and whether these associations varied by race and
prostate cancer grade. Low grade prostate cancer was
defined as Gleason sum <8 and high-grade prostate can-
cer was defined as Gleason ≥ 8. Potential confounders
(age, height, and BMI) were normally distributed overall
and were treated as continuous variables in modeling.
Race was self-reported and categorized as African
American, Caucasian and other (Native American and
Latino). Family history of prostate cancer included ma-
ternal lineage (maternal uncle) or paternal lineage
(father, brother or paternal uncle) (yes or no) and these
combined. Data on tobacco use at the time of enroll-
ment was also self-reported as yes or no.
Descriptive statistics (means, SD), and percentages for
cases and controls were estimated using X2 tests for cat-
egorical variables, and Wilcoxon rank-sum test for con-
tinuous variables. Unconditional logistic regression was
used to estimate the odd ratios (ORs) and 95% confidenceintervals (95% CI) for the association between genotypes
and prostate cancer risk. Multinomial logistic regression
models were used to explore whether associations be-
tween genotypes and prostate cancer risk varied by grade
of prostate cancer at diagnosis, using controls as reference.
Confounders adjusted for in all models were age, race, and
BMI. All analyses were done using SAS version 9.3 (SAS
Institute, Inc., Cary, NC).
Results
Table 2 describes the clinical characteristics of the study
participants. Prostate cancer cases (n = 233) and controls
(n = 342) were comparable in height (p = 0.31), however
controls (mean BMI = 30.77, SD = 6.05) had slightly higher
BMI than cases (mean BMI = 29.25, SD = 5.60, p = 0.002)
and were slighter younger than cases (p = 0.005). African
American men comprised 63% of the cases and 41% of
the controls (p <0.0001). A family history of prostate
cancer was reported by 14% of cases and 10% of the
controls. (p = 0.16). Most cases and controls reported
tobacco use (p = 0.43). Ninety-one percent of the cases
had low-grade prostate cancer (Gleason sum < 8) vs. 9% of
cases with high grade prostate cancer (Gleason sum ≥ 8).
The functional variants of the UGT2B15 and UGT2B17
SNPs were assessed for associations with prostate can-
cer risk and summarized in Table 3. After adjusting for
age, race and BMI, four UGT2B15 SNPs, rs9994887,
rs13112099, rs7686914 and rs7696472, were associated
with increased risk of prostate cancer, when compared
to the minor allele (Log additive model OR = 1.49, 95%
CI = 1.09, 2.04; OR = 1.48, 95% CI = 1.08, 2.03, OR =
1.48, 95% CI = 1.08, 2.03, OR = 1.49, 95% CI = 1.06, 2.00,
respectively). UGT2B15 SNPs rs4148269 and rs3100,
were also associated with increased risk for prostate
cancer (Log additive model OR = 1.45, 95% CI = 1.03,
2.03; OR = 1.46, 95% CI = 1.08, 1.98, respectively). These
data suggest that these associations were allele dose-
dependent (Table 3). None of the UGT2B17 SNPs studied
were associated with prostate cancer risk, however the
UGT2B17 cis-acting SNP, rs17147338, showed borderline
significance for increased risk of prostate cancer in an
allele dose dependent fashion (OR = 1.65, 95% CI = 1.00,
2.70), after adjusting for age, race and BMI (Table 3). SNPs
in high LD with UGT2B15D85Y, rs9994887, rs13112099,
Table 4 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in low grade and high grade PC cases
SNP # Allele Low gleason <8
n (%)
Adjusted OR
(95% CI)
High gleason ≥8
n (%)
Adjusted OR*
(95% CI)
UGT2B15
rs1580083
TT 0 (0) Reference 2 (10.00) Reference
TA 139 (65.88) – 10 (50.00) 0.20 (0.02-2.42)
AA 72 (34.12) – 8 (40.00) 0.33 (0.02-4.36)
AA/TA 211 (100.0) – 18 (90.00) 0.13 (0.02-0.74)
Log additive – 3.20 (0.30-33.45)
rs1960773
TT 0 (0) Reference 1 (5.26) Reference
GT 132 (63.16) – 11 (57.89) –
GG 77 (36.84) – 7 (36.84) –
GG/GT 209 (100.0) – 18 (94.73) –
Log additive – –
rs9994887
AA 32 (15.17) Reference 5 (25.00) Reference
AG 101 (47.87) 2.13 (1.13-4.00) 7 (35.00) 0.86 (0.19-3.80)
GG 78 (36.97) 2.53 (1.30-4.99) 8 (40.00) 1.27 (0.26-6.17)
GG/AG 179 (84.83) 2.27 (1.24-4.14) 15 (75.00) 1.00 (0.25-3.90)
Log additive 1.94 (1.06-3.53) 2.34 (1.22-4.49)
rs13112099
TT 32 (15.16) Reference 5 (25.00) Reference
GT 103 (48.81) 2.12 (1.13-3.98) 7 (35.00) 0.84 (0.19-3.71)
GG 76 (36.01) 2.50 (1.26-4.93) 8 (40.00) 1.30 (0.26-6.28)
GG/GT 179 (84.83) 2.25 (1.23-4.10) 15 (75.00) 1.00 (0.25-3.87)
Log additive 1.93 (1.06-3.52) 2.31 (1.20-4.44)
rs7686914
TT 32 (15.23) Reference 7 (36.83) Reference
CT 102 (48.57) 2.14 (1.14-4.02) 7 (36.84) 0.86 (0.19-3.78)
CC 76 (36.19) 2.50 (1.26-4.92) 5 (26.32) 1.30 (0.26-6.30)
CC/CT 178 (84.76) 2.25 (1.23-4.13) 12 (63.16) 1.00 (0.26-3.92)
Log additive 1.94 (1.06-3.54) 2.31 (1.20-4.44)
rs7696472
AA 32 (15.17) Reference 8 (40.00) Reference
AG 103 (48.82) 2.20 (1.16-4.12) 7 (35.00) 0.86 (0.19-3.82)
GG 76 (36.02) 2.43 (1.23-4.81) 5 (25.00) 1.26 (0.26-6.11)
GG/AG 179 (84.83) 2.30 (1.25-4.16) 12 (60.00) 1.00 (0.26-3.92)
Log additive 1.99 (1.10-3.63) 2.26 (1.18-4.33)
rs4148269
CC 38 (18.18) Reference 5 (26.32) Reference
CA 66 (31.58) 0.76 (0.42-1.40) 5 (26.32) 2.16 (0.23-20.26)
AA 105 (50.24) 1.70 (0.86-3.36) 9 (47.36) 13.55 (1.34-136.99)
AA/CA 171 (81.81) 1.00 (0.56-1.74) 14 (73.68) 3.94 (0.47-2.58)
Log additive 0.81 (0.45-1.47) 1.96 (1.01-3.82)
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Table 4 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in low grade and high grade PC cases
(Continued)
rs3100
TT 46 (22.33) Reference 7 (36.84) Reference
TC 64 (31.07) 1.04 (0.60-1.83) 4 (21.05) 1.10 (0.17-6.86)
CC 96 (46.60) 1.96 (1.06-3.63) 8 (42.10) 8.22 (1.31-51.60)
CC/TC 160 (77.66) 1.34 (0.81-2.22) 12 (63.16) 2.42 (0.50-11.83)
Log additive 1.04 (0.60-1.81) 2.16 (1.18-3.95)
rs2168047
AA 49 (23.22) Reference 3 (15.79) Reference
GA 99 (46.92) 0.78 (0.43-1.42) 12 (63.16) 2.61 (0.30-22.38)
GG 63 (29.86) 0.96 (0.50-1.84) 4 (21.05) 1.92 (0.18-20.07)
GG/GA 162 (76.77) 0.84 (0.48-1.48) 16 (84.21) 2.38 (0.30-19.86)
Log additive 0.85 (0.51-1.40) 1.01 (0.53-1.91)
rs6822259
CC 3 (1.43) Reference 0 (0) Reference
CT 50 (23.81) 1.25 (0.30-5.10) 7 (35.00) –
TT 157 (74.76) 1.27 (0.32-5.03) 13 (65.00) –
TT/CT 207 (98.57) 1.26 (0.32-4.95) 20 (100.00) –
Log additive 1.11 (0.68-1.79) –
rs17147338
CC 154 (72.99) Reference 12 (60.00) Reference
CT 48 (22.75) 1.64 (0.92-2.93) 7 (35.00) 2.78 (0.65-11.96)
TT 9 (4.27) 1.92 (0.30-12.18) 1 (5.00) 12.86 (0.91-181.95)
TT/CT 57 (27.01) 1.67 (0.94-2.91) 8 (40.00) 3.41 (0.89-13.08)
Log additive 1.70 (1.00-3.01) 2.44 (0.42-12.17)
UGT2B17
rs7435827
GG 50 (25.00) Reference 3 (16.67) Reference
GA 38 (19.00) 0.67 (0.34-1.31) 4 (22.22) 0.73 (0.11-4.72)
AA 112 (56.00) 0.87 (0.46-1.63) 11 (61.11) 1.33 (0.26-6.84)
AA/GA 150 (75.00) 0.78 (0.44-1.37) 15 (83.33) 1.03 (0.23-4.65)
Log additive 0.67 (0.35-1.32) 0.90 (0.49-1.66)
rs7686008
AA 154 (72.99) Reference 12 (60.00) Reference
AT 29 (13.74) 1.25 (0.61-2.58) 4 (20.00) 5.42 (1.05-27.96)
TT 28 (13.27) 1.30 (0.60-2.80) 4 (20.00) 5.05 (0.72-35.66)
TT/AT 57 (27.01) 1.27 (0.71-2.28) 8 (40.00) 5.30 (1.19-23.55)
Log additive 1.41 (0.70-2.84) 1.42 (0.67-3.01)
rs7671342
GG 34 (16.19) Reference 3 (14.28) Reference
GA 43 (20.48) 0.89 (0.44-1.81) 4 (19.05) 0.61 (0.08-4.60)
AA 133 (63.33) 1.31 (0.71-2.41) 14 (66.67) 1.28 (0.26-6.35)
AA/GA 176 (83.81) 1.17 (0.64-2.11) 18 (85.71) 1.05 (0.22-5.04)
Log additive 0.86 (0.43-1.73) 1.30 (0.72-2.36)
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Table 4 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in low grade and high grade PC cases
(Continued)
rs59678213
CC 40 (20.20) Reference 2 (11.76) Reference
TC 41 (20.71) 0.99 (0.54-1.81) 4 (23.53) 2.77 (0.27-28.17)
TT 117 (59.09) 0.76 (0.40-1.45) 11 (64.71) 3.60 (0.38-33.75)
TT/TC 158 (79.79) 0.76 (0.42-1.38) 15 (88.23) 3.21 (0.37-27.47)
Log additive 1.02 (0.56-1.82) 1.18 (0.63-2.21)
*Adjusted for age, race and BMI.
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http://www.biomedcentral.com/1471-2407/13/556rs7686914, and rs796472 [34] were associated with in-
creased risk of prostate cancer in an allele dose-dependent
manner for both high-grade (OR = 2.34, 95% CI = 1.22,
4.49; OR = 2.31, 95% CI = 1.20, 4.44; OR = 2.31, 95% CI =
1.20, 4.44; OR = 2.26, 95% CI = 1.18, 4.33, respectively)
and low-grade prostate cancer lesions (OR = 1.94, 95%
CI = 1.06, 3.53; OR = 1.93, 95% CI = 1.06, 3.52; OR =
1.94, 95% CI = 1.06, 3.53; OR = 1.99, 95% CI = 1.10, 3.63,
respectively) after adjusting for age, race, and BMI
(Table 4). Intriguingly, SNPs rs4148269 and rs3100 were
associated with increased PC risk in high grade lesions
only (OR = 1.96, 95% CI = 1.01, 3.82; OR = 2.16, 95% CI =
1.18, 3.95).
Restricting analyses by race/ethnicity, and after
adjusting for age and BMI, further revealed that these
associations were present in African American men
(rs9994887, OR = 1.66, 95% CI = 1.05, 2.63; rs13112099,
OR = 1.66, 95% CI = 1.03, 2.63; rs7686914, OR = 1.64,
95% CI = 1.03, 2.63; rs7696472, OR = 1.64, 95% CI =
1.03, 2.63; rs4148269, OR = 2.04, 95% CI = 1.19, 3.44;
and rs3100, OR = 1.89, 95% CI = 1.22, 2.94) (Table 5).
However, the interaction terms for these SNPs and race
were not statistically significant (p > 0.4) for all six
SNPs. For both groups, carrying the UGT2B17 or cis-
acting SNPs was not associated with prostate cancer
risk (Table 5).
To investigate the extent to which these SNPs were
associated in our subjects we calculated correlation
coefficients among the controls as shown in Table 6.
The r2 values for the UGT2B15 variants rs1580083,
rs1960773, rs13112099, rs7686914, rs7696472 and
rs9994887 ranged from 0.62 to 0.99/1.00 (p < 0.0001).
UGT2B15 variants rs4148269 and rs3100 were also
strongly correlated (r2 = 0.85, p < 0.0001). Including
both SNPs into the same regression model to evaluate
whether one SNP would have a stronger association
with PC risk did not yield additional insights. Notably,
these two SNPs showed no correlation with the other
SNPs that were highly associated with each other.
UGT2B17 SNP rs7435827 was moderately correlated
with UGT2B15 SNP rs2168047 (r2 = 0.36, p < 0.0001)
and UGT2B17 SNP rs7671342 (r2 = 0.32, p < 0.0001),
and strongly correlated with UGT2B17 SNP rs59678213(r2 = 0.83, p < 0.0001); however these SNPs showed no
association with prostate cancer risk. UGT2B17 SNP
rs59678213 was inversely associated with UGT2B17 SNPs
rs2168047 (r2 = −0.47, p < 0.0001), rs7686008 (r2 = −0.29,
p < 0.0001) and rs7671342 (r2 = −0.49, p < 0.0001). No cor-
relations were observed for the cis-acting UGT2B SNPs
that were identified through the recent UGT2B SNPs dis-
covery study [38]. All SNPs that showed associations with
prostate cancer risk were in Hardy-Weinberg equilibrium
in control samples, except for UGT2B15 SNP rs3100.
Discussion and conclusion
In this study we examined associations between functional
SNPs of the UDP-glucuronosyltransferase 2B (UGT2B)
genes and prostate cancer risk. After adjusting for age and
BMI, we found that two UGT2B15 SNPs, rs4148269 and
rs3100, were associated with a two-fold increase risk of
prostate cancer and the association was more apparent in
African American men. In addition, SNPs rs9994887,
rs13112099, rs7686914 and rs7696472 were also associ-
ated with increased risk of prostate cancer. These associa-
tions persisted either in low or high-grade prostate cancer
lesions for SNPs rs9994887, rs13112099, rs7686914, and
rs7696472. However, SNPs rs4148269 and rs3100 were
only associated with increased risk of prostate cancer in
high-grade prostate cancer lesions. These findings are
novel and support the hypothesis that these SNPs may
affect UDP-glucuronosyltransferase enzyme function,
presumably by increasing the efficiency of androgen
metabolite clearance compared to enzyme products of
the UGT2B wild type genotype, as has been shown for
UGT2B15 SNP rs1902023 [21].
Associations between functional SNPs of the UGT2B15
and UGT2B17 genes and prostate cancer risk have been
previously examined and have rendered conflicting results
[22-32]. Discrepancies could be due in part to racial/ethnic
differences in the populations studied but also to sample
size and allele dosage. Comparison of two studies with
different sample sizes revealed contradictory results: no
associations between SNP UGT2B15D85Y and prostate
cancer risk were found in a study with a large sample size
[9], whereas a study with a smaller sample size found an
increased risk of prostate cancer associated with the
Table 5 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in African American and
Caucasian men
African American Caucasian
SNP # Allele Cases
n (%)
Controls
n (%)
Adjusted OR (95% CI)* Cases
n (%)
Controls
n (%)
Adjusted OR (95% CI)*
UGT2B15
rs1580083
TT 0 (0) 1 (0.72) Reference 2 (2.30) 4 (20.9) Reference
TA 86 (58.90) 94 (68.12) — 64 (73.56) 155 (77.11) 1.22 (0.10-14.43)
AA 60 (41.10) 43 (31.16) — 21 (24.14) 42 (1.99) 1.36 (0.11-16.96)
AA/TA 146 (100.0) 137 (99.27) — 85 (97.70) 159 (79.1) 1.25 (0.11-14.73)
Log additive – 1.12 (0.58-2.17)
rs1960773
TT 0 (0) 2 (1.45) Reference 1 (1.16) 3 (23.38) Reference
GT 82 (56.94) 93 (67.39) – 62 (72.09) 151 (75.12) –
GG 62 (43.06) 43 (31.16) - 23 (26.74) 47 (1.49) –
GG/GT 144 (100.0) 136 (98.55) – 85 (98.83) 198 (76.62) –
Log additive – –
rs9994887
AA 16 (10.96) 28 (20.44) Reference 22 (25.29) 63 (31.50) Reference
AG 65 (44.52) 63 (45.99) 1.92 (0.72-5.10) 43 (49.43) 93 (46.50) 1.93 (0.90-4.14)
GG 65 (44.52) 46 (33.58) 2.96 (1.09-8.04) 22 (25.29) 44 (22.00) 1.87 (0.77-4.54)
GG/AG 130 (89.04) 109 (79.56) 2.34 (0.93-5.88) 65 (74.71) 137 (68.50) 1.91 (0.92-3.96)
Log additive 1.66 (1.05-2.63) 1.35 (0.88-2.08)
rs13112099
TT 16 (10.96) 28 (20.00) Reference 22 (25.29) 63 (31.18) Reference
GT 67 (45.89) 68 (48.57) 1.96 (0.74-5.20) 43 (49.43) 95 (47.03) 1.88 (0.88-4.05)
GG 63 (43.15) 44 (31.43) 2.94 (1.07-8.05) 22 (25.29) 44 (21.78) 1.87 (0.77-4.54)
GG/GT 130 (89.04) 112 (80.00) 2.34 (0.93-5.88) 65 (74.71) 139 (68.81) 1.88 (0.91-3.91)
Log additive 1.66 (1.03-2.63) 1.35 (0.88-2.08)
rs7686914
TT 16 (11.03) 28 (20.14) Reference 22 (25.58) 63 (31.50) Reference
CT 67 (46.21) 67 (48.20) 2.00 (0.75-5.31) 42 (48.84) 93 (46.50) 1.88 (0.87-4.05)
CC 62 (42.75) 44 (31.65) 2.94 (1.07-8.05) 22 (25.58) 44 (22.00) 1.87 (0.77-4.54)
CC/CT 129 (88.96) 111 (79.86) 2.37 (0.94-5.96) 64 (74.42) 137 (68.50) 1.88 (0.91-3.91)
Log additive 1.64 (1.03-2.63) 1.35 (0.88-2.08
rs7696472
GG 16 (10.96) 29 (20.70) Reference 22 (25.29) 63 (31.66) Reference
AG 67 (45.89) 67 (47.86) 1.96 (0.74-5.20) 43 (49.43) 90 (45.23) 2.01 (0.93-4.32)
AA 63 (43.15) 44 (31.43) 2.94 (1.07-8.05) 22 (25.29) 46 (23.12) 1.77 (0.73-4.27)
AA/AG 130 (89.04) 111 (79.28) 2.34 (0.93-5.88) 65 (74.71) 136 (68.34) 1.93 (0.93-4.04)
Log additive 1.64 (1.03-2.63) 1.31 (0.86-2.00)
rs4148269
CC 9 (6.25) 11 (7.86) Reference 34 (39.53) 68 (34.00) Reference
CA 34 (23.61) 58 (41.43) 0.73 (0.20-2.70) 38 (44.19) 102 (51.00) 0.89 (0.46-1.73)
AA 101 (70.14) 71 (50.71) 2.34 (0.67-7.83) 14 (16.28) 30 (15.00) 1.46 (0.57-3.77)
AA/CA 135 (93.75) 129 (92.14) 1.65 (0.51-5.34) 52 (60.46) 132 (66.00) 0.99 (0.53-1.85)
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Table 5 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in African American and
Caucasian men (Continued)
Log additive 2.04 (1.19-3.44) 1.12 (0.71-1.75)
rs3100
TT 18 (12.86) 32 (23.02) Reference 36 (41.38) 74 (36.63) Reference
TC 31 (22.14) 42 (30.22) 1.57 (0.54-4.55) 37 (42.53) 98 (48.51) 0.91 (0.47-1.72)
CC 91 (65.00) 65 (46.76) 3.36 (1.36-8.30) 14 (16.09) 30 (14.85) 1.48 (0.58-3.78)
CC/TC 122 (87.14) 107 (76.97) 2.75 (1.15-6.58) 51 (58.62) 128 (63.36) 1.00 (0.54-1.84)
Log additive 1.89 (1.22-2.94) 1.12 (0.72-1.75)
Cis acting on UGT2B expression
rs2168047
AA 42 (28.97) 36 (26.09) Reference 11 (12.64) 23 (11.50) Reference
GA 69 (47.59) 65 (47.10) 0.83 (0.39-1.75) 43 (49.43) 104 (52.00) 0.92 (0.35-2.42)
GG 34 (23.44) 37 (26.81) 0.91 (0.37-2.21) 33 (37.94) 73 (36.50) 1.07 (0.39-2.93)
GG/GA 103 (71.03) 102 (73.91) 0.85 (0.42-1.72) 76 (87.35) 177 (88.50) 0.98 (0.38-2.48)
Log additive 0.94 (0.61-1.47) 1.07 (0.67-1.72)
rs6822259
CC 1 (0.69) 4 (2.86) Reference 2 (2.30) 8 (3.98) Reference
CT 25 (17.24) 38 (27.14) 0.61 (0.03-10.56) 33 (37.93) 59 (29.35) 1.60 (0.86-2.96)
TT 119 (82.07) 98 (70.00) 0.91 (0.05-14.99) 52 (59.77) 134 (66.67) 0.70 (0.14-3.54)
TT/CT 144 (99.31) 136 (97.14) 0.83(0.05-13.61) 85 (97.70) 193 (96.01) 1.47 (0.81-2.67)
Log additive 1.34 (0.68-2.77) 1.23 (0.75-2.03)
rs17147338
TT 91 (62.33) 100 (71.43) Reference 77 (88.51) 0 (0) Reference
CT 46 (31.51) 35 (25.00) 1.72 (0.84-3.54) 9 (10.34) 16 (7.96) –
CC 9 (6.16) 5 (3.57) 1.51 (0.23-9.88) 1 (1.15) 185 (92.04) –
CC/CT 55 (37.67) 40 (28.57) 1.70 (0.85-3.40) 10 (11.49) 16 (7.96) –
Log additive 1.53 (0.84-2.82) –
UGT2B17
rs7435827
GG 13 (9.35) 13 (9.56) Reference 40 (50.00) 93 (49.21) Reference
GA 22 (15.83) 27 (19.85) 0.47 (0.12-1.92) 21 (26.25) 51 (26.98) 0.78 (0.37-1.66)
AA 104 (74.82) 96 (70.59) 0.80 (0.24-2.68) 19 (23.75) 45 (23.81) 0.86 (0.40-1.85)
AA/GA 126 (90.65) 123 (90.44) 0.72 (0.22-2.41) 40 (50.00) 96 (50.79) 0.82 (0.44-1.52)
Log additive 1.08 (0.64-1.85) 1.08 (0.75-1.59)
rs7686008
AA 83 (56.85) 92 (66.19) Reference 84 (96.55) 189 (93.56) Reference
AT 32 (21.92) 25 (17.99) 1.65 (0.74-3.69) 2 (2.3) 7 (3.47) 0.70 (0.13-3.71)
TT 31 (21.23) 22 (15.83) 1.51 (0.67-3.44) 1 (1.15) 6 (2.97) 0.99 (0.10-10.04)
TT/AT 63 (43.15) 47 (33.81) 1.58 (0.83-3.01) 3 (3.45) 13 (6.44) 0.78 ( 0.20-3.08)
Log additive 1.28 (0.86-1.90) 0.88 (0.33-2.36)
rs7671342
GG 22 (15.07) 23 (16.43) Reference 15 (17.44) 33 (16.34) Reference
GA 25 (17.12) 35 (25.00) 0.66 (0.24-1.88) 21 (24.42) 50 (24.75) 1.06 (0.42-2.67)
AA 99 (67.81) 82 (58.57) 1.51 (0.63-3.64) 50 (58.14) 119 (58.91) 1.15 (0.51-2.59)
AA/GA 124 (84.93) 117 (83.57) 1.21 (0.52-2.84) 71 (82.55) 169 (83.66) 1.12 (0.51-2.46)
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Table 5 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in African American and
Caucasian men (Continued)
Log additive 1.36 (0.90-2.08) 1.07 (0.73-1.59)
rs59678213
CC 10 (7.35) 8 (5.97) Reference 32 (40.00) 73 (40.11) Reference
TC 19 (13.97) 24 (17.91) 0.45 (0.10-2.00) 27 (33.75) 50 (27.47) 1.04 (0.49-2.20)
TT 107 (78.68) 102 (76.12) 0.65 (0.18-2.41) 21 (26.25) 59 (32.42) 0.80 (0.37-1.71)
TT/TC 126 (92.65) 126 (94.02) 0.62 (0.17-2.24) 48 (60.00) 109 (59.89) 0.91 (0.48-1.73)
Log additive 0.99 (0.64-1.69) 1.11 (0.76-1.61)
*Adjusted for age and BMI.
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http://www.biomedcentral.com/1471-2407/13/556UGT2B15D85Y variant in Caucasian subjects [32]. In refer-
ence to allele dosage, we previously concluded [33], con-
cordant with previous reports [31,32,39], that homozygous
carriers of the dominant UGT2B15D85Y (G) allele missense
polymorphism, (rs1902023), had an almost three-fold
higher risk of prostate cancer. Our current results
further confirm that associations with UGT2B15 poly-
morphisms are allele dose-dependent and may also be
dependent on race/ethnicity. Furthermore, our study
includes a large and multiethnic sample size in com-
parison to previous reports.
Some of our stratified analyses revealed that UGT2B15
wild type alleles were significantly associated with in-
creased risk of prostate cancer in African American
men, but not in Caucasian men, suggesting that the wild
type genotype may confer protection against prostate
cancer in Caucasian men. While these findings require
replication in larger studies, we provide new evidence
that wild type genotypes for the UGT2B15 gene more
frequently found in African American men may in-
crease the risk of prostate cancer, and thus may contrib-
ute to the present racial/ethnical disparities seen in
prostate cancer incidence. Few studies have assessed the
association of UGT2B genes with prostate cancer risk in
African Americans. Park et al. [25] were one of the first
to report that associations between UGT2B17 polymor-
phisms and increased risk of prostate cancer were
linked to race/ethnicity; they showed that Caucasian
men carrying a UGT2B17 deletion polymorphism had a
two-fold increased risk of prostate cancer, but not Black
men who carry the same deletion, compared to non-
carriers [25]. Subsequent work supported these findings
[22,26], which were further confirmed by others [23,24].
Our results show no significant associations of UGT2B17
polymorphisms with prostate cancer risk in neither
Caucasian nor African American men. Our findings
that UGT2B17 SNP rs59678213 was not associated
with prostate cancer risk are consistent with those of
others [22,24].
Four of the UGT2B15 SNPs that conferred prostate can-
cer risk in this study are among seven SNPs (rs1580083,
rs1960773, rs9994887, rs13112099, rs7686914, rs7696472,and rs1120265 [not in study]) that are in high linkage dis-
equilibrium (LD) with UGT2B15D85Y SNP rs1902023 [34].
The phenotype of the variations, established with reporter
gene assays in the liver cancer cell line HepG2, showed
that transcriptional activity was higher for constructs con-
taining the major alleles when compared to constructs
containing the minor alleles. When a construct with the
minor allele of rs9994887 was transfected into a prostate
cancer cell line, LNCaP, transcriptional activity was de-
creased by approximately 14%, compared to constructs
containing the major allele [34], which suggested that
rs9994887 may influence gene expression in the prostate
[34]. Further experiments would have to be done to deter-
mine the impact of these variants on the kinetics and effi-
cacy of UGT2B enzymes. Interestingly, the other three
SNPs that showed associations with increased prostate
cancer risk, rs13112099, rs7686914, and rs7696472 were
highly correlated with rs9994887 (r2 = 0.99, 0.99, and 0.97,
respectively). In addition, the three SNPs are all located
upstream of rs9994887 (−1139 bp relative to translation
start) while the other two SNPs are located downstream.
While the impact of these variants on UGT2B15 enzyme
kinetics has not been reported, the associations suggest
that the phenotype of the enzyme may be similar to
that of the UGT2B1585Y variant or rs1902023 [19].
SNPs rs4148269 and rs3100 also demonstrated strong
associations with decreased risk of PC, but did not
show any correlation with the promoter SNPs in this
study population. SNP rs4148269 has been character-
ized as a T523K amino acid substitution [40], however
a comprehensive analysis of the enzyme phenotype has
not been reported. This suggests that rs3100, which is
highly correlated (r2 = 0.85) with rs4148269, may be
important in the etiology of PC. Results from reporter
gene assays showed that the major allele of rs3100 is
associated with significantly higher gene expression in
LNCaP cells when compared to constructs made with
the minor allele [36].
The lack of association observed for the UGT2B17 SNPs
and PC risk was unexpected, as previous reports suggested
that the UGT2B17 enzyme plays a major role in testoster-
one glucuronidation [20]. However results from a recent
Table 6 Spearman correlation coefficients and p values for UGT2B15 and UGT2B17 SNPs
rs1580083 rs1960073 rs9994887 rs13112099 rs7686914 rs7696472 rs4148269 rs3100 rs2168047 rs6822259 rs17147338 rs7435827 rs7686008 rs7671342
rs1580083 1.000 0.894 0.625 0.637 0.638 0.625 0.002 0.000 0.000 0.000 0.002 0.001 0.000 0.002
<.0001 <.0001 <.0001 <.0001 <.0001 0.458 0.780 0.749 0.873 0.366 0.527 0.720 0.414
rs1960073 0.894 1.000 0.631 0.650 0.645 0.631 0.001 0.000 0.001 0.001 0.002 0.000 0.000 0.003
<.0001 <.0001 <.0001 <.0001 <.0001 0.669 0.931 0.634 0.614 0.366 0.946 0.686 0.284
rs9994887 0.625 0.631 1.000 0.989 0.989 0.973 0.000 0.000 0.002 0.000 0.003 0.010 0.001 0.006
<.0001 <.0001 <.0001 <.0001 <.0001 0.685 0.776 0.384 0.894 0.296 0.069 0.549 0.145
rs13112099 0.637 0.650 0.989 1.000 1.000 0.984 0.001 0.070 0.002 0.000 0.004 0.009 0.001 0.005
<.0001 <.0001 <.0001 <.0001 <.0001 0.033 0.627 0.461 0.970 0.263 0.093 0.510 0.176
rs7686914 0.638 0.645 0.989 1.000 1.000 0.984 0.001 0.001 0.002 0.000 0.004 0.009 0.001 0.005
<.0001 <.0001 <.0001 <.0001 <.0001 0.033 0.627 0.462 0.970 0.264 0.094 0.510 0.177
rs7696472 0.625 0.631 0.973 0.984 0.984 1.000 0.002 0.002 0.001 0.000 0.003 0.007 0.001 0.006
<.0001 <.0001 <.0001 <.0001 <.0001 0.044 0.443 0.523 0.961 0.282 0.139 0.619 0.161
rs4148269 0.002 0.001 0.000 0.001 0.001 0.002 1.000 0.849 0.000 0.000 0.007 0.046 0.059 0.021
0.458 0.669 0.685 0.550 0.550 0.4217 <.0001 0.854 0.753 0.122 0.0001 <.0001 0.008
rs3100 0.000 0.000 0.000 0.070 0.001 0.002 0.849 1.000 0.003 0.001 0.002 0.018 0.021 0.015
0.780 0.931 0.776 0.627 0.627 0.443 <.0001 0.332 0.530 0.362 0.016 0.007 0.023
rs2168047 0.000 0.001 0.002 0.002 0.002 0.001 0.000 0.003 1.000 0.007 0.001 0.356 0.043 0.139
0.749 0.634 0.384 0.461 0.462 0.523 0.854 0.332 0.135 0.549 <.0001 0.0001 <.0001
rs6822259 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.001 0.007 1.000 0.023 0.004 0.006 0.000
0.873 0.614 0.894 0.970 0.970 0.961 0.753 0.530 0.135 0.005 0.279 0.170 0.825
rs17147338 0.002 0.002 0.003 0.004 0.004 0.003 0.007 0.002 0.001 0.023 1.000 0.005 0.000 0.000
0.366 0.366 0.295 0.263 0.264 0.282 0.122 0.362 0.549 0.005 0.223 0.895 0.873
rs7435827 0.001 0.000 0.010 0.009 0.009 0.007 0.046 0.018 0.356 0.004 0.005 1.000 0.162 0.318
0.527 0.946 0.069 0.093 0.093 0.139 0.0001 0.016 <.0001 0.279 0.223 <.0001 <.0001
rs7686008 0.000 0.000 0.001 0.001 0.001 0.001 0.059 0.021 0.043 0.006 0.000 0.162 1.000 0.047
0.720 0.686 0.549 0.510 0.510 0.619 <.0001 0.007 0.0001 0.170 0.895 <.0001 <.0001
rs7671342 0.002 0.003 0.006 0.005 0.005 0.006 0.021 0.015 0.139 0.000 0.000 0.318 0.047 1.000
0.414 0.284 0.145 0.176 0.177 0.161 0.008 0.023 <.0001 0.825 0.873 <.0001 <.0001
rs59678213 0.032 −0.001 0.078 0.071 0.070 0.058 0.116 0.045 −0.473 0.086 −0.077 0.830 −0.494 1.000
0.577 0.985 0.170 0.211 0.213 0.303 0.034 0.42 <0.0001 0.217 0.168 <0.0001 <0.001
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http://www.biomedcentral.com/1471-2407/13/556report comparing UGT2B17 and UGT2B15 mRNA and
protein expression, suggest that UGT2B15 may be nega-
tively regulated in naïve and castration-resistant tumors
while undetectable in lymph node metastases [41]. More
in vitro analyses are required to understand the functional
impact of these genetic variations. Nonetheless this is the
first time these SNPs are reported in relation to prostate
cancer risk.
The main limitation of this study is the sample size
which limited our ability to simultaneously examine
race/ethnicity in the associations with SNPs and pros-
tate cancer grade. The low numbers of Caucasians may
have limited our ability to detect significant associations
within this group given that they were less likely to
present a high grade PC tumor. The small sample size
could also have been a contributing factor in the lack of
significance for the cross-product term for the SNPs
and race, however race/ethnicity was self-reported and
we did not measure ancestral markers, which could
indicate the percentage of African American ancestry of
each subject. Also, we cannot exclude the possibility of
potential confounding due to differences in MAFs be-
tween races. Nonetheless our study was conducted at the
DVAMC which provides medical care for all former mili-
tary personnel. This type of setting has important advan-
tages. The Veterans Affairs Medical Centers (VAMC)
are considered an equal-access health care settings that
may control for health care availability among various
U.S. ethnicities [42]. Moreover, the VAMCs provide a
setting for PC case–control studies as this is the leading
cancer reported in Veterans Affairs Central Registry
(VACCR) [43].
Despite these limitations, in the current case–control
study of African American and Caucasian men, we ob-
served elevated risk of prostate cancer in African American
men who carry the wild type of the functional UGT2B15
gene variants. Future studies with larger sample sizes are
needed to confirm these findings.
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